Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with ...

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

Usha (name changed), 62, was experiencing sudden and painless loss of vision in the right eye for one day when she turned up ...

Diabetes can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye ...